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ABSTRACT 
Phenotypic screening is an effective approach to the discovery of small-molecule drugs. In 
this thesis, I have used cancer cells grown as 3D microtissues (multicellular spheroids) to 
study the effect of anticancer drugs and as drug discovery tools. Most clinically used 
cytotoxic drugs have only modest efficacy on spheroids, possibly explaining their limited 
efficacy on many solid tumors. We therefore used spheroids as targets for screening 
campaigns aimed to discover novel anti-cancer drugs. This work resulted in the identification 
of compounds that showed preferential cytotoxicity to spheroids compared to monolayer 
cultures. We also used multicellular spheroids to study regrowth of cells after cytotoxic 
therapy.  
The compound VLX600 was identified in our spheroid screening work. This drug was found 
to induce autophagy and upregulation of glycolysis in tumor cells. Further work showed that 
VLX600 is an inhibitor of mitochondrial oxidative phosphorylation. The work has lead to the 
hypothesis that cells in the deep tumor parenchyme are sensitive to disturbances of energy 
metabolism due to lack of metabolic plasticity. Our studies demonstrated that VLX600 also 
decreased the levels of c-MYC. This phenomenon was also observed after treatment with 
other mitochondrial inhibitors. An additional screen was performed using glucose-deprived 
spheroids. This screen identified five molecules that showed selectivity to spheroids. All five 
drugs were found to inhibit mitochondrial respiration. The FDA-approved antiprotozoal drug 
nitazoxanide was chosen for further studies and may be a candidate for future clinical trials. 
Increased glycolysis in tumor cells leads to the generation of metabolic acids and a 
subsequent acidification of the microenvironment of solid tumors. We found that tumor 
acidosis leads to induction of autophagy and present evidence that autophagy is a 
mechanism for cancer cells to adapt to an acidic environment. 
We conclude from this work that multicellular spheroids can be used to screen for novel 
anticancer agents. Several drugs identified by this approach were found to be inhibitors of 
mitochondrial function. This finding suggests a therapeutic strategy to target quiescent tumor 
cells in metabolically compromised microenvironments.  
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1 INTRODUCTION  
1.1 CANCER—A COMPLEX AND CHRONIC DISEASE 
1.1.1  What is cancer? 
A report from the nation's leading cancer organization has shown that, in the United States 
only, there were ~ 1,665,000 new cases (not including non-melanoma skin cancers) and ~ 
585,000 cancer-related deaths in 2014.1,2 Cancer Research UK has reported that nearly 
76,000 people die from cancer each year in the UK (more than 40 per cent of the total 
individuals who die early), compared to 28,000 who die from heart disease (15 per cent) and 
17,000 from respiratory diseases (9 per cent).3-5 Cancer has become one of the biggest killers 
in world.  
Records of cancer can date back to the days of the great pyramids.6 The first description 
about cancer can be traced back to 3000 B.C., although the word "cancer" was not used. In an 
ancient Egyptian text, 8 cases of tumors were described and the conclusion about the disease 
was sadly made as "There is no treatment".7 
The word "cancer" was initially used by the Greek physician Hippocrates (460-370 BC), the 
person who is regarded as the "Father of Medicine". Hippocrates used the terms carcinos and 
carcinoma, which were referred to a crab in Greek and later translated into cancer, to 
describe non-ulcer forming and ulcer-forming tumors.7,8 
As late as 30-40 years ago, our understanding of cancer was limited (the "riddle of cancer"). 
We could only see tumors when they were already big enough, weigh them, and calculate its 
size, but few tools could be used to really know what had happened inside of cancer cells. 
Some talent researchers were ahead of their periods, for example Rudolf Virchow, a German 
doctor and known as the "People of medicine", used microscope firstly observed the blood 
disease and now named as leukemia as well as firstly brought up the theory that cancers came 
from the over-active dormant cells.9 Stephen Paget, the scientist who in 1889 brought up the 
seed-and-soil hypothesis of metastasis. According to his theory, tumor cells were compared 
to seeds and distant organs were compared to soil: "When a plant goes to seed, its seeds are 
carried in all directions but they can only live and grow if they fall on congenial soil."10,11 The 
comprehension of biology and genetics was for many years too primitive to allow an 
understanding of the causes of cancer. Oswald Avery showed in 1944 that genetic 
information was transmitted by deoxyribonucleic (DNA) and not by proteins.12 A decade 
later Watson and Crick published a model for the structure of DNA.13 Research in the 1970s 
and 1980s subsequently showed that cancer is a disease induced by gene mutations.   
Cancer is now recognized as a complex disease where abnormal cells divide out of control 
and may acquire the ability to invade and to spread to other tissues,1 the underlying cause of 
this abnormal phenotype is mutations in the genome.1,8,14,15 The mutations of these genes lead 
to defects in proteins that control signalling pathways that relate to cell growth, proliferation, 
metabolism.14,16-18 
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In 2000, Hanahan and Weinberg described the six hallmarks of cancer19 to describe the 
multistep development of human tumors: self-sufficiency in growth signalling, insensitivity 
to anti-growth signals, evading apoptosis, sustained angiogenesis, endless proliferation and 
tissue invasion metastasis.19 In 2011, Hanahan and Weinberg further developed their theory: 
their acquisition is made possible by the enabling characteristics—the development of 
genomic instability and tumor-promoting inflammation. And the emerging hallmarks: 
reprogramming energy metabolism and avoiding immune destruction.20  An overview of the 
hallmarks of cancer is shown in Figure 1.  
 
Figure 1: The hallmarks of cancer and enabling characteristics A) Illustration of the six hallmark 
capabilities originally proposed in 2000 perspective. B) Further illustration of enabling characteristics and 
emerging hallmarks in 2011.19,20 
 
Cancer types can be grouped into broader categories. The main categories of cancer are 
Carcinoma – a malignant tumor composed of epithelia cells. Sarcoma - cancer that begins in 
bone, cartilage, fat, muscle, blood vessels, or other connective or supportive tissue; Leukemia 
- cancer that starts in blood-forming tissue such as the bone marrow and causes large numbers 
of abnormal blood cells to be produced and enter the blood; Lymphoma and myeloma - 
cancers that begin in the cells of the immune system and Central nervous system cancers - 
cancers that begin in the tissues of the brain and spinal cord. Cancer names can always be 
based on where they start, for example, cancer that begins in the breast is called breast cancer; 
cancer that starts in lung is lung cancer.1,21-25 
 
1.1.2 Cancer metabolism 
Cancer cells have for many years been noted to have alterations in their metabolism. This 
phenomenon, observed by researchers nearly 100 years ago, now is termed one of the 
fundamental hallmarks of cancer.26 Normal cells produce adenosine triphosphate (ATP) 
mainly by glycolysis together with oxygen consumption from the highly efficient 
mitochondrial oxidative phosphorylation (OXPHOS). Already in the 1920s Otto Warburg 
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demonstrated that tumor cells had elevated glucose consumption compared to normal cells, 
but glucose did not form H2O and CO2 that were generated from OXPHOS, but instead 
formed lactate from pyruvate. This increase in lactate formation occurred no matter whether 
there was sufficient oxygen or not. This phenomenon was termed the "Warburg effect" or 
aerobic glycolysis.27 Clinical research have indicated that glycolysis-related genes are found 
overexpressed in almost 70% of all human cancers,28 The increased uptake of the glucose 
analogue 18F-fluorodeoxyglucose by cancer cells can be utilized for diagnostic purposes.29 
The enhanced glycolytic flux may confer a growth advantage in tumor cells. Recent findings 
suggest a more complex situation where cancer cells take up more glucose but at the same 
time they still depend on functional mitochondria and OXPHOS to meet their high energy 
demands.30-35 I will return to this theme later in this thesis.  
In addition to up-regulation of glycolysis, glutaminolysis also increases in order to sustain 
nicotinamide adenine dinucleotide phosphate (NADPH) regeneration. Glutamine carbons 
replenish the Krebs cycle, yet produces metabolites that can be used for macromolecular 
biosynthesis, like nucleic acids, proteins, and carbohydrates.36-39 It has also been shown that 
in addition to glucose and glutamine, which are involved in supporting energy metabolism 
and anabolic processes, one-carbon molecules, which are mainly refueled by the chemical 
reactions of folate compounds, also play important roles in integrating cellular nutrient 
status.40,41 Reactions carry out in a cyclical path and during reactions, a carbon unit is 
transferred to other metabolic pathways and eventually generated diverse outputs, including 
redox maintenance and cellular biosynthesis.28,42,43 44,45  Figure 2 is a simple overview of 
metabolic activities in cancer cells.46  
 
  
 
 
 
 
 
 
 
 
 
Figure 2: An overview of metabolic activities in cancer cells.  Glycolysis and glutamiolysis are up 
regulated in tumor cells. One-carbon molecules that can be from serine and glycine metabolism also play 
important roles in integrating cellular nutrient status. 
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The underlying reasons for the metabolism changes of cancer cells have been pursued by 
many researches. Metabolic reprogramming may be a consequence of "survival of the fittest". 
First, in solid tumors, cancer cells distant from blood vessels will not be able to obtain 
sufficient oxygen for OXPHOS to generate enough ATP to sustain their increased energy. In 
addition to energy production, tumor cells also require various building block molecules for 
anabolic processes, which can be fulfilled by glycolysis and glutaminolysis.14,16-18,38,47,48 Last 
but not the least, lactate, the product of glycolysis, plays a key role in tumor progression, 
tumor metastasis, immune escape and resistance to cancer therapy.29,49-52 All these factors 
may be the reasons for the metabolic changes of cancer cells. 
 
1.1.3 Tumor microenvironment (TME) (solid tumor) 
The microenvironmental physiology of tumors can be characterized by hypoxia, extracellular 
acidosis and nutrient deprivation,53 which are quite different from normal cells.  
1.1.3.1 Hypoxia 
Hypoxia is a characterization of solid tumors that can be classified into hypoxic hypoxia and 
chemical hypoxia. 
Hypoxic hypoxia 
The presence of hypoxic hypoxia in human solid tumors, which is due to an imbalance 
between the supply and consumption of oxygen, was firstly proved by Thomlinson and Gray 
some 50 years ago.54 In clinical, investigators define the regions, where [pO2 values] ≤ 2.5 
mm Hg, as hypoxic areas in solid tumors. The major causes involved in the process of 
hypoxic hypoxia are: 
(1) The tumor microvessels have severe structural and functional abnormalities (perfusion-
limited O2 delivery), which are often transient.53,55 
(2) A degeneration of the diffusion geometry (diffusion-limited O2 delivery), which can be 
induced by an increase of the diffusion distance to blood vessels.55,56  
(3) The decreased surface to volume ratio S/V (S: surface area, V: the volume of the viable 
rim, S=4πr2 and V=4/3πr3 (r= radius), the ratio of S/V is 3/r) thus restricting the area through 
which oxygen diffuse into solid tumors (this conclusion was from the spheroids study).57,58  
Tumor hypoxic hypoxia causes a severe problem in radiation therapies, because the low pO2 
value reduces the ROS-mediated fixation efficacy of DNA damage.59-61   
Tumor cells in hypoxic regions are also considered to be resistant to most anticancer drugs. 
Firstly, the distance from blood vessels and the limited drug permeabilization ability (i.e. 
doxorubicin) make tumor cells not adequately exposed to anticancer reagents. Secondly, 
cancer cell proliferation is often impaired in hypoxic regions, due to the growth arrest by 
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HIF-1α dependent induction of p21, p27 and p53.62 Drugs that target proliferating tumor cell 
will not be effective on these quiescent cancer cells.63,64 
Chemical hypoxia  
The definition of chemical hypoxia is that the accumulating of reductive equivalents caused 
inhibition of respiration chain in mitochondria and it is independent of the 
microenvironmental oxygen level.65,66,49 
Such reducing equivalents include endogenous molecules, like glutathione (GSH) or 
pyruvate, as well as exogenous pharmacological substances, like inhibitors of mitochondrial 
respiration chain. A common effect of chemical hypoxia is the shifting cellular redox state 
towards a strongly reduced cellular environment by reductive molecules, which is also able to 
interrupt ROS-mediated fixation of DNA damage.49  
1.1.3.2  Extracellular acidosis 
Intensive glycolysis in tumor cells will result in extracellular acidosis. Under glycolysis, 
glucose does not form H2O and CO2 from OXPHOS, but lactate from pyruvate. The 
production of lactic acid leads to acidification in tumor microenvironment.17,53,67-70 
The acidic pH of the tumor microenvironment is believed to play an important role in tumor 
metastasis, genetic instability and malignant progression.71-76 Data from clinical studies has 
shown that high lactate concentrations are associated with high incidence of distance 
metastasis and low survival probability in both human cervix carcinoma and human head & 
neck cancer.52,77-79 Moreover, some anticancer drugs that are always work at physiological 
pH (≈7.4) can be ineffective at low pH. For example, chloroquine (CQ), which is currently 
evaluated in clinical trials, shows anticancer effect in neutral pH, yet, does not work well in 
acidic environment.73  
1.1.3.3  Nutrient deprivation  
Tumors are usually characterized by nutrient deprivation. This happens both in rapidly 
proliferating areas and quiescent tumor cells that are far from blood vessels, due to inefficacy 
of nutrition diffusion.63,80-82 Experiments using the multicellular spheroids (MTS) model with 
quantitative bioluminescence and single photon imaging have shown that there is a strong 
decrease of glucose concentrations from the outer-rim of spheroids towards the core, from > 
21 µmol/g to ≈ 0 µmol/g.83-86 
Hypoxia, extracellular acidosis and nutrient deprivation associate with each other and the 
relations between them are addressed in Figure 3.87  
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Figure 3: An overview of the tumor microenvironment. A) Diagrammatic representation of tumor cells 
surrounding a capillary. B) Schematic representation of the gradient of oxygen concentration, pH and glucose 
concentration.  
 
1.1.4 Cancer characterizations  
Cancer cells reprogram their biological functions at different levels in order to meet 
demanding on their high proliferation and overcome cell death after cancer treatments. Here, 
several different characters, which are also important considerations in my study, are 
described below: 
1.1.4.1 c-MYC is de-regulated in many tumors 
The CMYC proto-oncogene, which was first discovered as an inducer of retrovirally mediated 
tumorigenesis, belongs to the myelocytomatosis oncogene family (MYC) that also contains 
MYCN (N-myc) and MYCL (L-myc),88-90 which evolve from myc-like genes found in 
drosophila and hydra.91,92 In human, the c-MYC oncogene is overexpressed in at least 40% of 
cancers and serves as a "master regulator" of cellular metabolism and proliferation.89,93,94 
C-MYC is an early response gene to growth factor stimulation. As c-MYC is able to cause 
tumorigenesis, its activation in many normal cells is always restrained through multiple 
genetic and epigenetically controlled checkpoint mechanisms, including proliferative arrest, 
apoptosis, and cellular senescence. For example, in the absence of nutrients, c-MYC gene 
expression is down regulated in normal cells in order to stop proliferation. In contrast, when 
c-MYC is oncogenically activated, for example, by chromosomal translocation or gene 
amplification, c-MYC bypasses these restrained checkpoints and enforces many of the 
“hallmark” features of cancer, including unlimited cellular proliferation, a constitutive 
biomass accumulation, altered cellular metabolism and a condition addictive to nutrients.95-101  
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C-MYC, the oncoprotein encoded by c-MYC gene, is a basic helix–loop–helix–leucine zipper 
(bHLH–ZIP) transcription factor whose known biological activities require interactions with 
the bHLH–ZIP protein Max.102,103 The MYC-Max complex is involved in the control of a 
wide array of cellular activities (Figure 4),94 like cell mass regulation, cell survival and is a 
master regulator of metabolic processes including glycolysis, oxidative phosphorylation and 
mitochondrial biogenesis.92,104,105  
The first suggestion that c-MYC has a great importance in regulation of glycolysis is the 
observation that lactate dehydrogenase A (LDHA), which converts pyruvate to lactate as part 
of the glycolytic pathway, is a c-MYC target.106,107 Mitochondrial generation of acetyl-CoA is 
dependent on c-MYC.108,109 Moreover, it has been reported that c-MYC directly regulates 
mitochondrial transcription factor A (TFAM), which encodes a key factor involved in 
mitochondrial transcription and mitochondrial DNA (mtDNA) replication.110 Interestingly, c-
MYC recently has been shown to be able to alter glutamine metabolism by transcriptionally 
repressing miRNAs, like miR-23a and miR-23b.111-113 
Since c-MYC oncoprotein takes part in different kinds of important cellular processes and 
biological functions in tumor cells, researchers have attempted to inhibit its activity trough 
different approaches.104 For example, JQ1, which is a selective inhibitor of bromodomain 
protein, leads to downregulation of c-MYC.111,114-118 Researchers also have attempted to use 
c-MYC antisense oligonucleotides, which has been encouraging in vitro but failed to translate 
into effective clinical treatments.119-121 Moreover, in some experiments, c-MYC suppression 
has initially resulted in a tumor regression but subsequently recurred.122 The c-MYC-Max 
complex has also been reported to be a target for pharmacological inhibitors. The small 
molecule 10058-F4 has been reported to specifically inhibit the c-MYC-Max complex 
formation and the growth of c-MYC overexpressed cells in vitro (>50µΜ),92,123 No drug that 
targets c-MYC has been shown a strong antitumor effect in animal models, and no such drug 
has to my knowledge been tested in clinical trials.  
 
 
 
 
 
 
 
 
 
 
Figure 4: Myc-max complex affects almost every activity of cell life. 
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1.1.4.2 Autophagy is up-regulated in tumors  
Autophagy, which is a catabolic process used by eukaryotic cells to recycle long-lived 
proteins, lipids, and clear up protein aggregates and organelles, is up-regulated for tumor cell 
survival in acidic and nutritionally deprived environments.71,124-126 Recent studies have 
revealed the importance of autophagy in development,127,128 aging,129 and pathophysiology 
such as neurodegenerative disease, obesity and cancer.130-134 The mammalian target of 
rapamycin complex 1 (mTORC1) is a major checkpoint in signalling pathways and regulates 
autophagy. It integrates signalling through the PI3K/Akt pathway and cellular nutrient status 
or energy levels, which are sensed by AMP-activated kinase (AMPK). 4E-BP1 and p-70-S6 
kinase, which regulate protein synthesis, are the key downstream effectors of mTORC1.135-137 
Decreases of their phosphorylation termed a sign of mTOR inhibition and autophagy 
activation in cells.138,139 
Autophagy starts from the formation of a double membrane-bound autophagosome mediated 
by autophagy-related protein (ATG) proteins.130,140 and the whole process can be simply 
described as Figure 5: A portion of cytoplasm, including organelles, is enclosed by a 
phagophore to form an autophagosome. The outer membrane of the autophagosome first 
fuses with the endosome and then with the lysosome. The internal material is then degraded 
in matured autolysosome.126,141-143 
 
 
 
 
 
 
 
 
 
 
Figure 5: The process of autophagy in mammalian cells. A portion of cytoplasm, including organelles, is 
enclosed by a phagophore to form an autophagosome. The outer membrane of the autophagosome first fuses 
with the endosome and then with the lysosome. The internal material is then degraded in matured autolysosome. 
 
In cancer progression, autophagy plays a complex role at different stages. At the tumor 
initiation stage, autophagy is a tumor suppressor in order to limit the production of reactive 
oxygen species (ROS) and DNA damage.125,132 However, autophagy is used as a survival 
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pathway by tumor cells to overcome metabolic stress and cell death in response to the 
changing microenvironment and cancer therapies.71,133,134 Because of this, autophagy is 
viewed as a druggable process in cancer treatment.142,144-149 For example, 3-methyladenine 
(3-MA), which is the most widely used autophagy inhibitor for in vitro experiments.150,151 
Chloroquine (CQ) which was firstly used for malaria also has shown an anti-cancer effect 
as an autophagy inhibitor.73,152-155 The latest autophagy inhibitor lys05, a dimeric 
chloroquine, produces more potent antitumor activity as a single agent both in vitro and in 
vivo in several human cancer cell lines and xenograft models.156,157 
1.1.4.3  Aerobic glycolysis in tumor cells 
Glycolysis (from glycose [an older term for glucose] + -lysis degradation) is a metabolic 
pathway that converses per glucose to two pyruvates molecules, generating 2 molecules of 
ATP and 2 molecules of NADH.  
Glucose + 2NAD+ + 2ADP + 2P --> 2pyruvate + 2ATP + 2NADH + 2H+ 158 
In most mammalian cells, glycolysis is inhibited by the presence of oxygen, which allows 
mitochondria to oxidize pyruvate to CO2 and H2O by OXPHOS system. This inhibition is 
termed the Pasteur effect, named after Louis Pasteur, who first demonstrated that glucose 
flux was reduced by the presence of oxygen.159 Rapidly growing tumor cells typically have 
glycolytic rates that are up to 200 times higher than those of their normal cells and after 
glycolysis, pyruvate was finally fermented to lactate. This phenomenon was first described in 
1927 by Otto Warburg and is referred to as the Warburg effect27,160 and has later been 
confirmed by numerous investigators.161-165  
As we know, glycolysis can only produce 2 ATP by digesting per glucose, whereas between 
30 and 36 ATPs are produced by the oxidative phosphorylation.166 And lactate, the 
production of glycolysis, causes an acidification of the extracellular space, which might result 
in cellular toxicity. So, why do tumor cells still prefer glycolysis? 
With increased tumor size, cancer cells, gradually far from blood vessels, are not able to 
obtain sufficient oxygen and oxidative phosphorylation (OXPHOS) pathway will be 
impaired. The hypoxia-inducible factor 1 (HIF1), which is a hypoxia-generated signal and 
termed the key regulator of oxygen homeostasis,167-169 actives the transcription of genes 
encoding glycolytic enzymes (such as phosphoglycerate kinase 1 and pyruvate kinase M).168-
171 The upregulation of glycolysis will have significant negative consequences, due to 
extracellular acidosis. Tumor cells upregulate Na+–H+ exchange and vacuolar H+-ATPases, 
undergo mutations or epigenetic changes to adapt extracellular acidification.172-175 When 
tumor cells bypass this crucial evolutionary selection, they are able to take advantage of the 
local acidic microenvironment, compete with normal cells and transit from pre-malignant 
lesions to invasive cancer (Figure 6).18,47,53,176-178 At the same time, these biological changes 
also make tumor cells more resistance to cancer therapies.68,70,179,180 
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Figure 6: Function of glycolysis on cancer progression.  Normal epithelial cells (pink) become hyper 
proliferative following induction (orange). As they reach the oxygen diffusion limit, they become hypoxic 
(yellow) and either lead to cell death or adaptation of a glycolytic phenotype, which allows cells to survive. 
As a consequence of glycolysis, lesions become acidotic, which selects for motile cells (black) that eventually 
breach the basement membrane.47  
 
1.1.4.4  Mitochondrial function —not really impaired 
The mitochondrial bacterium was engulfed around 1.5 billion years ago since then lived 
within eukaryotic cells as a symbiotic partner (endosymbiotic theory).181 The mitochondrion 
(Figure 7A) is sometimes referred to as the ˝powerhouse of the cells˝.182 The mitochondrial 
DNA (mtDNA) encodes the 13 most important OXPHOS genes, and the nuclear DNA 
(nDNA) contains all of the remaining OXPHOS genes, as well as the genes responsible for 
mitochondrial metabolism and biogenesis.183,184  
The mitochondrion is a double-membrane organelle (Figure 7B). The electron transport chain 
(ETC) (Figure 7C) locates in the inner membrane. The ETC contains four components, 
complexes I, II, III, and IV, together with substrates, cofactors, and the paths of electron 
flow183,185-187 to generate a proton gradient. This gradient is applied to produce ATP, which is 
later used as a source of chemical energy in mammalian cells.188,189         
In addition to supplying cellular energy, mitochondria also are involved in other tasks such as 
signalling, cellular differentiation, cell death, as well as maintaining the control of cell 
growth. Until today, mitochondria have been implicated in several human diseases (e.g. 
Parkinson’s, Alzheimer’s, Lou Gehrig’s disease) and may play a role in the aging process and 
termed one of the important organelles in mammalian cells.190,191 
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Figure 7: The structure and electron transport chain of mitochondria. A: Mitochondrial structure under 
transmission electron microscopy B: Basic structure of the mitochondrion. C: Basic components on the 
mitochondrial electron transport chain.  
 
Warburg observed that glycolysis is up-regulated in tumor cells because of the impaired 
mitochondrial metabolism.27 The result is true, but the reason now has been proven incorrect. 
In the pioneering studies, mitochondrial function was determined by measuring the products 
both from oxidative phosphorylation and glycolysis.192-194 But it is worth noting that the 
glycolytic rate is usually determined by measuring the lactate production, whereas, during the 
reaction, the concentrations of the substrates and variations of oxygen concentrations in vitro 
and in vivo can both affect result of the measurements.195-197 Some recent reports have shown 
that despite the accelerated glycolysis in many fast-growth tumor cells, its total contribution 
to the cellular ATP supply only reaches 10%.196 This might indicate that the mitochondrial 
oxidative phosphorylation still take an important role in tumor cells. Another strong argument 
to mitochondrial impairment in cancer cells is from experiments of generating various 
mtDNA eliminated cancer cells (rho0) by growing tumor cells in medium with ethidium 
bromide (EtBr). The rho0 cancer cells show a dropped growth rate, decreased colony 
formation and markedly reduced tumor formation in nude mice.198-204 
Mitochondrial mutations are observed in tumors, presumably in order to better meet altered 
metabolic demands. There are two classes of mutations in mtDNA of cancer cells: a) 
mutations that serve to stimulate neoplastic transformation and b) mutations that assistant 
cancer cells accommodating to the constantly changing bioenergetic environments.205-208                  
In addition to mtDNA mutations, many mitochondrial proteins or enzymes that are coded by 
nuclear DNA also become mutated in cancer cells. For example: the mutant isocitrate 
dehydrogenase (IDH) proteins decrease NADPH levels and then inhibit glutathione 
peroxidase (GPx) that can reduce H2O2 to water. The increased level of H2O2 can contribute 
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to neoplastic transformation.209-214 The succinate dehydrogenase (SDH), which is a 
complex II protein on mitochondrial electron transport chain, is inhibited due to the 
mutation of its subunits. Subsequently, HIF1α is stabilized215 and causes a shift from 
oxidative phosphorylation to glycolytic energy metabolism.209  
It is likely that glycolytic and oxidative metabolisms undergo dynamic changes in 
proliferated and transformed cancer cells, as a result of varying selective pressures in terms of 
nutrients and oxygen availability. Even if OXPHOS becomes impaired, mitochondria still 
have a great importance in cell signalling, cell cycle and cell death regulation.183,216-221 It is 
also true that mitochondria are controlled or regulated by other proteins (like CMYC, Hsp90 
and VEGF),222-231 cellular biological process (mitophogy and proteasome degradation)228-231 
in tumors.  
In present researches, targeting mitochondria or its related substrates is regarded as a 
therapeutic strategy in cancer treatment. For example lonidamine, which is already used in 
clinic phase trial.232-234  3-bromopyruvate (3-BrPA), a lactate/pyruvate analogue, is an 
alkylating agent and a potent inhibitor of glycolysis.235,236 2-deoxy-D-glucose (2-DG), not 
targeting mitochondria, but is a glucose analogue that worked as a competitive inhibitor of 
glucose metabolism and can be combined with radiotherapies in cancer treatment.237-239 
In Paper II, we show that a compound, which is identified in a screen for drugs and decreases 
tumor spheroids viability, is a mitochondrial inhibitor. In paper IV, we found that targeting 
mitochondria in tumor cells decreases CMYC levels. In paper V, we demonstrated that a 
number of drugs identified by screening multicellular spheroids are all mitochondrial 
inhibitors. These findings indicate that functional mitochondria are potential targets for 
cancer therapeutics. 
 
1.2 CANCER TREATMENT—STILL ON THE WAY 
1.2.1 Cancer treatment 
In the early 20th century, only small and localized tumors could be completely removed by 
surgery. Later, radiation was used to treat tumors that could not be removed by surgery. The 
period of cancer chemotherapy began in the 1940s with the first use of nitrogen mustards to 
treat lymphomas and folic acid antagonist drugs on leukemia. 240,241 Later, chemotherapy was 
used to treat colon cancer, testicular cancer, and other tumors. Nowadays, cancer therapies 
include surgery, radiation, chemotherapy, hormone therapy, immunotherapy and targeted 
therapies. In clinic, a combination of therapies is frequently used in order to achieve optimal 
results.21,242,243  
Chemotherapies generally target the process of DNA replication or target the cell division 
process. This results in toxicity to proliferating normal cells and cause side effects on 
patients. Targeted therapies are being developed which are more specific to tumor cells 
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(mutant receptors, activated kinases etc.). Targeted therapies work by influencing the 
processes (mostly proteins) that control growth, division, and spread of cancer cells, as well 
as the signals that cause cancer cells to die naturally, for example the proteasome inhibitor 
bortezomib (Velcade®) and the BCR-ABL inhibitor imatinib (Gleevec®) and etc.242  
Over the past 25 years, more and more researches have indicated that many signalling 
pathways are involved together in tumor cell formation and progression. This leads to 
questioning the strategy that only target individual signalling molecules. More and more 
researchers start to agree that targeting metabolic differences between normal cells and tumor 
cells can be an applicable strategy in cancer therapy.17 
 
1.2.2 Chemotherapeutic drugs 
Chemotherapy has been used in anticancer treatment for about seventy years.21 During the 
last 20 years, around 180 anticancer drugs have been approved by FDA and used in clinic.244 
Based on their chemical structure and mechanism of action, these drugs are classified as: 
• Alkylating agents and platinum compounds 
• Antibiotics 
• Antimetabolites 
• Topoisomerase I and II inhibitors 
• Mitosis inhibitors 
• Others 
This kind of classification serves two main objectives: obtaining an overview of the available 
drugs and designing new combination therapies.245-247 
1.2.2.1 Alkylating agents and platinum agents 
Alkylating agents work by covalent modification of intracellular macromolecules. They may 
have one or two reactive groups (monofunctional or bifunctional agents). Monofunctional 
agents modify only one base in DNA and cause DNA single-stand breaks. Bifunctional 
agents form crosslinks between biological molecules and may cause DNA interstrand 
crosslinking. Alkylating agents directly damage DNA and prevent cancer cells from 
reproducing. These agents are not cell phase specific, since they damage DNA, tissues 
characterized by rapid proliferation, such as the bone marrow that can get long-term injury 
after alkylating agents treatment.247,248 There are different classes of alkylating agents, 
including： 
• Nitrogen mustards: mechlorethamine, chlorambucil, cyclophosphamide (Cytoxan®), 
ifosfamide, and melphalan 
• Nitrosoureas: streptozocin, carmustine (BCNU), and lomustine  
• Alkyl sulfonates: busulfan 
• Triazines: dacarbazine (DTIC) and temozolomide (Temodar®)  
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• Ethylenimines: thiotepa and altretamine (hexamethylmelamine) 
1.2.2.2 Antibiotics 
This type of drugs interferes with enzymes involved in DNA replication and work in all 
phases of the cell cycle. They are widely used for a variety of cancers. A major consideration 
is that antibiotics can cause permanent damage to the heart if high doses is given.248 
Examples of antibiotics:  
• Daunorubicin 
• Doxorubicin (Adriamycin®)  
• Epirubicin  
• Idarubicin 
1.2.2.3 Antimetabolites  
Antimetabolites have structures that are similar to natural existing substances, such as amino 
acid or nucleosides. They usually compete with natural substrates for the active sites on key 
enzymes or receptors.249,250 Antimetabolites can interfere with DNA replication and/or RNA 
transcription. These agents damage cells during the S phase. They are commonly used to treat 
leukemia, cancers of the breast, ovary, and the intestinal tract.15,248,250 Examples of 
antimetabolites include:  
1.2.2.4 Topoisomerase I and II inhibitors 
This type of inhibitors interact with enzymes called topoisomerases and are involved in a 
number of DNA-related events, such as DNA replication, transcription, recombination, 
chromosome condensation and segregation.251-256 Topoisomerase inhibition results in DNA 
double strand breaks, inhibition of cell proliferation and/or apoptosis. These drugs are phase-
specific and prevent cells from entering mitosis. Examples of topoisomerase inhibitors:  
• Topoisomerase I inhibitors: Topotecan, Camptosar, Irinotecan and etc. 
• Topoisomerase II inhibitors: Teniposide, Etoposide (VP-16), Doxorubicin, 
Daunorubicin, Amsacrine, Aurintricarboxylic acid, Mitoxantrone and etc. 
 
•      Fludarabine  •      5-fluorouracil (5-FU)  
•      Gemcitabine (Gemzar®) •      6-mercaptopurine (6-MP)  
•      Hydroxyurea  •      Capecitabine (Xeloda®)  
•      Methotrexate  •      Clofarabine  
•      Pemetrexed (Alimta®)  •      Cytarabine (Ara-C®)  
•      Pentostatin  •    Floxuridine 
•      Thioguanine •       Cladribine 
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1.2.2.5  Mitosis inhibitors (tubulin inhibitor) 
Mitotic inhibitors are often plant alkaloids and other compounds derived from natural 
products. They can stop mitosis or inhibit enzymes from making proteins that are needed for 
cell reproduction.257,258 
These drugs work during the M phase of the cell cycle but can damage cells in all phases. 
They are used to treat many different types of cancer including breast cancer, lung cancer, 
myelomas, lymphomas, and leukemias. Mitotic inhibitors have a potential to cause peripheral 
nerve damage, which can be a dose-limiting side effect.248,259-261  
1.2.2.6 Mitochondrial inhibitors 
The mitochondrion is the energy supplier in cells; it generates 80%–90% ATP for cell 
survival and plays an essential role in the integration of pro-apoptotic and anti-apoptotic 
stimuli. Cancer cells reprogram their mitochondrial function in order to meet their different 
energy requirements.245,262,263  
Normally, there are two kinds of mitochondrial inhibitors in cancer therapies. The first class 
contains the drugs that directly target mitochondria and induce mitochondrial impairment or 
dysfunction. For example, 2-methoxyestradiol (2-ME), which is used in photodynamic 
anticancer therapy, causes an accumulation of ROS by inhibition of the superoxide dismutase 
(SOD) activity and ensuing cytotoxic effects.245,264 Lonidamine is another anti-cancer drug 
that already used in Phase II pilot study of chemotherapy in patients with metastatic breast 
adenocarcinoma. It has a direct effect on adenine nucleotide translocase (ANT) that localized 
in the mitochondrial inner membrane and cause mitochondrial membrane permeability 
(MMP).234,265,266 Metformin, used in diabetes before, recently has been reported as a 
mitochondrial complex I inhibitor.267-269 The second class includes drugs that mitochondrial 
dysfunction is their second effects. For example, inhibiting topoisomerase II, which is 
extracted from mitochondria, induces mtDNA breaks.270,271  
1.2.2.7 Targeted therapies 
Nowadays, researchers also have begun to synthesize new drugs that attack cancer cells more 
specifically than traditional chemotherapy drugs. The new generation of chemotherapy drugs 
will specifically target mutant versions of certain genes or cells that express too many copies 
of a particular gene. These drugs can be used as part of the main treatment, or they may be 
used after treatment to maintain remission or decrease the chance of recurrence.272-275 
Examples of targeted therapies include: 
• Imatinib (Gleevec®)— BCR-ABL inhibitors 
• Cetuximab (Erbitux®)—EGFR inhibitors 
• Vemurafenib (Zelboraf®)— BRAF inhibitors 
• Bortezomib(Velcade®)— Proteasome inhibitors 
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1.2.3 Cancer resistance and relapse 
Chemoresistance is a major problem and one main reason of failure in cancer treatment.276 
Normally, chemoresistance includes two different categories: intrinsic and acquired.  
Intrinsic drug resistance is a term used to describe the fact that tumor cells may show natural 
resistance to certain therapies.277  
One possible reason to explain the intrinsic drug resistance of tumor cells is their high levels 
of expression of p-glycoprotein (P-gp).278-282 P-gp, an efflux pump, is the product of the 
MDR1 (multi-drug resistance) gene in human. This protein can detect and bind many 
hydrophobic natural-product drugs (doxorubicin, vinblastine and etc.) when these drugs 
enter the plasma membrane and release them back into the extracellular space.283-285 Recent 
study has indicated that, in solid growing tumors, extracellular acidosis leads to an 
increased P-gp activity, which is pH-dependent.286  
Another possible reason is their high extracellular acidosis. It has been reported that lactate 
concentrations in term of µmol/g which can be considered mM in viable tumor regions.83 
And high extracellular acidosis results in the enhanced tumor anti-oxidant capacity that might 
impair anticancer drug efficacy, which works mainly by inducing ROS-mediated fixation of 
DNA in tumor cells.49  
Acquired drug resistance means that tumor cells initially are sensitive to drugs but due to 
mutations and various adaptive responses during drug treatment, tumor cells gradually gain 
resistance and become insensitive to drugs.277 Acquired drug resistance is a more complex 
cell response to anticancer drugs and a result of constantly selection for tumor cell survival 
and proliferation.280,287 
Reasons of tumor cell acquired drug resistance include a) decreased drug uptake and 
increased drug efflux,280,287,288 b) mutation or alteration of the expression of a drug 
target,16,270,289 c) DNA reparation,290 d) deregulation of apoptosis291 and e) autophagy 
upregulation.292-294 
 
1.2.4 Models for new anti-cancer drug discoveries 
1.2.4.1 Traditional approaches  
Traditionally, there are two major approaches to discover new anticancer drugs, one is the 
biochemical screen for drugs that target specific molecules and the other is cell-based 
phenotypic screening.295 The biochemical screen for specific target is able to screen hundreds 
of thousands of compound within a relative short time. Cell-based assays have the advantage 
that a pharmacological effect is known to be elicited by a hit compound. A problem with cell 
based screens is that the target(s)/mechanism of action of the hit compounds must be 
identified. Approaches such as connectivity map (Cmap)296 and drug affinity responsive 
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target stability (DARTS)297-299 have been developed in recent years and test methods are 
quite useful for target identification/finding molecular mechanism of action.  
1.2.4.2 Multicellular spheroids (MTS) model 
Monolayer cultures are not able to mimic the real tumor hypoxic and nutrient-deprived 
microenvironments of solid tumors. Furthermore, penetration of anticancer agents into the 
parenchyma of solid tumors limits their efficacy in vivo, but does not influence drug activity 
on monolayer cultures. Today, these shortcomings increase the risk of failures in vivo.80,300-307 
Multicellular spheroids represent an in vitro tumor model in which cancer cells are supplied 
by the diffusion of substrates from the surrounding growth medium.58 Multicellular spheroid 
model was adapted to cancer researches in the early 1970s by Sutherland and colleges307,308 
and is in use in many laboratories throughout the world today. 
One major advantage of multicellular spheroids is their well-defined geometry, which makes 
it possible to directly relate structure to function.309 The other advantage is that its biological 
pattern (like microenvironment and proliferation gradient) and other activities (metabolism, 
cell death, drug resistance) are more close to that in living organisms.58,304,310 Figure 8 is an 
overview of  the spheroid characterizations and how structure influences the function in 
spheroids. 
 
 
 
 
 
 
 
 
Figure 8:  An overview of multicellular spheroids. A) Sections of HCT116 colon cancer cells, stained for 
Ki67, p27Kip1, pimonidazole adducts or Bip. B) Tumor cells are in different status and the concentrations of 
glucose, lactate, ATP and O2 are different from the out-rim of spheroids towards the core.58,193,311,312-315
 
 
Multicellular spheroids have been used as models to investigate the impacts of different 
factors, such as pH, oxygen and glucose levels, on cell metabolism, proliferation and 
viability. A number of important biological questions such as cell cycle checkpoints,316 the 
role of E-cadherin in the induction of apoptosis,317 and the role of HIF1-1α on the malignant 
phenotype have been studied in the multicellular spheroid model.318  Multicellular spheroids 
model have been widely used in studies of cancer therapeutic drugs and more recently in 
cancer drug discover.71,302,304,319,320 
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1.2.4.3 High-throughput multicellular spheroids screening  
Spheroid cultures are known to more closely mimic the properties of tumor tissue than 
monolayer cultures with regard to growth kinetics and metabolic rates.300,303 Nutrients, 
oxygen, and waste products do not diffuse freely in and out of spheroids.304,309 Tumor cell 
lines are in general more resistant to anticancer agents when the cells are grown as 3-
dimensional spheroids rather than monolayer cultures.305,321 The resistance of spheroids to 
anticancer drugs appears to reflect both limited drug penetration into the inner regions of the 
3-dimensional cell populations as well as acquired resistance at the multicellular level.305,322 
The gene expression patterns of cells grown in monolayer cultures and as spheroids differ, 
and some differences can be attributed to intrinsic drug sensitivity.301,323 For these reasons, 
MTS model-based drug development is regarded as an important step before in vivo 
experiments (Figure 9).  
 
  
Figure 9: An overview of drug development processes. 
The traditional method to generate multicellular spheroids was to use spinner cultures. The 
resulting spheroids are heterogeneous in size and cannot be used for drug screening. A 
method that is capable of generating individual and uniformly sized spheroids in hanging 
drops has subsequently been described. Spheroids are generated in inverted microwell trays 
and then transferred by pipette to agar-coated 48-well plates,322,323 this method is time-
consuming, and other methods have been developed more suitable for screening. Our group 
uses a procedure based on the principle of hanging drop but spheroids are generated directly 
in 96-well plates (avoiding pipetting steps to transfer the spheroids).304   
In most of our experiments we use high glucose medium (4.5 g/L; 25 mM). These conditions 
are unphysiological but allow the production of 500 µm spheroids after 5 days culturing 
containing a large central core of hypoxic cells. Cells in the core area are quiescent, based on 
negative staining for the proliferation marker Ki67 and positive staining for p27Kip1 (Figure 1 
in paper I). The presence of a significant proportion of hypoxic/quiescent cells in spheroids is 
expected to improve the sensitivity of screening for drugs that act on these cell populations. 
We initially used the method acid phosphatase assay324 to determine cell viability and the 
M30 Apoptosence method325 to measure apoptosis of drug-treated spheroids. These methods 
do not rely on the addition of exogenous substrates that need to penetrate into spheroids. In 
Paper V we used cells expressing green fluorescent protein (GFP) in a spheroid screen in a 
384-well format.  
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2 AIM OF THE THESIS 
The aim of the thesis is to develop therapeutic strategies for quiescent tumor cell populations, 
which are resistant to chemotherapy and a major problem in clinical oncology.  
The specific aim of each paper included in this thesis is described below: 
Paper I: We here found that the PI3KCA (phosphatidylinositol 3-kinase catalytic subunit) 
mutation in HCT116 colon cancer cells is essential for spheroid growth. This observation 
prompted us to examine the effect of pharmacological inhibition of the PI3K/mTOR 
pathway on spheroid viability.  
Paper II: The aim of this study was to screen a chemical library for compounds that reduce 
the viability of spheroids. The work resulted in the identification of the compound VLX600. 
This drug was found to decrease mitochondrial OXPHOS, induce metabolism shift and to 
trigger the death of both proliferating and quiescent tumors.    
Paper III: The aim of this paper was to contribute to the understanding of the role of tumor 
autophagy. We found that autophagy is a survival mechanism of tumor cells in acidic 
conditions. 
Paper IV: The aim of this study was to provide insight in the ability of VLX600 to induce 
growth inhibition of cells cultured in monolayer (paper II).  We found that VLX600 
decreases the level of c-MYC protein in tumor cells and this effect appears to be associated 
with mitochondrial impairment.  
Paper V: The aim of this paper was to examine to extend the screen of paper II to get more 
information on the mechanism of action of drugs that affect spheroid viability. Several 
promising compounds, which also target mitochondria, were identified. 
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2 RESULTS AND DISCUSSION 
2.1  PAPER I:  
Studies of tumor cell regrowth after cytotoxic therapy: using an mTOR/PI3K inhibitor to 
prevent tumor cell regrowth. 
Background: Regrowth of tumor cells between cycles of chemotherapy is a significant 
problem in cancer therapy.326-328 Regrowth is believed to occur from populations of cells in 
the deep tumor parenchyme that are slowly proliferating and comparatively insensitive to 
many clinically used drugs. Strategies to control regrowth of these cell populations may 
improve the results of treatment of solid tumors.  
Methods: Colon carcinoma cells with wild type, mutant phosphatidylinositol 3-kinase 
catalytic subunit (PI3KCA) or Kirsten rat sarcoma viral oncogene homolog (KRAS) alleles 
were allowed to form multicellular spheroids. The effects of different pharmacological 
inhibitors on the growth of colon carcinoma spheroids were examined. 
Results: HCT116 colon carcinoma multicellular spheroids were found to have hypoxic and 
quiescent tumor cells in the core, and proliferating cells in outer layers. A number of 
clinically used chemotherapeutical agents had limited cytotoxic effect on these spheroids, 
consistent with published data.  
Secondly, our data suggest that the PI3KCA mutation in HCT116 cells is required for the 
growth of these cells as spheroids. In contrast, disruption of the PI3KCAmut allele had only a 
minor influence on the rate of proliferation of HCT116 cells in monolayer culture. In 
contrast to the strong effect on MTS growth by disruption of the mutant PI3KCA allele, 
KRASwt/– cells showed a similar rate of spheroid growth as the KRASwt/mut parental cells. In 
fact, the difference in the proliferation rate of these cells was larger in monolayer culture.  
Thirdly, we used methyl-13-hydroxy-15-oxokaurenoate (MHOK) to study tumor cell 
regrowth after treatment. Regrowth after exposure to most drugs was difficult to study since 
MTS contain an outer rim of dead cells, which made it difficult to estimate the real size of the 
viable portion of the spheroids. MHOK was identified in a drug screen for compounds 
effective on multicellular spheroids304,329 Treatment with MHOK resulted in activation of 
caspase-3 in outer cell layers as early as after 4 h, followed by detachment of these cells. The 
remaining MTS cell masses have a defined border of viable cells, facilitating accurate 
determination of MTS size after drug exposure and further incubation. When MHOK-treated 
spheroids were monitored over time, MTS volumes started to increase after a lag period. We 
conclude from these experiments that the hypoxic cells of the HCT116 spheroid cores were 
able to reinitiate cell proliferation within 18 h after detachment of the outer cell layers and 
subsequent re-exposure to oxygen and nutrients. 
Finally, our findings suggest that inhibition of PI3K signalling might be effective in 
inhibition of regrowth of HCT116 MTS after cytotoxic therapy. We examined the effect of 
the dual pan-class PI3K/ mTORC1/mTORC2 inhibitor NVP-BEZ235.330 We found that 
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NVP-BEZ235 was effective in blocking regrowth of MTS after MHOK treatment. Sequential 
treatment with MHOK and NVP-BEZ235 reduced the volume of HCT116 MTS to <5% of 
the initial volume. 
Discussion: The results showed that PI3KCA mutation is required for growth of HCT116 
colon cancer cells in multicellular spheroids, whereas the KRAS mutation in these cells was 
not necessary for growth in the 3-D in vitro model. RAS genes are the most frequently 
mutated oncogenes detected in human cancer and interact with various effectors, in order to 
stimulate various downstream signalling pathways and regulate cell proliferation, 
differentiation, survival and death.331,332 KRAS is one isoform of RAS family (H-RAS, N-
RAS and K-RAS are R-RAS).333 It has been noticed that different RAS family members play 
different roles in tumor progression and invasion.334-336 For example, K-RAS was found to 
lead to a loss of cell–cell and cell–matrix adhesion.336-338 And this kind of loss might enhance 
the potential for invasion and metastasis. In contrast, H-RAS was found to be a much more 
effective activator of PI3Kinase.339 PI3Kinase family has a pivotal role in translating 
extracellular stimuli (e.g. growth factors, cytokines, hormones) into a broad range of cellular 
functions, such as cell cycle progression, cell growth, survival and apoptosis.340 Paper has 
indicated that growth was restricted significantly (p<0.0001) in a dose-dependent response in 
spheroids following treatment of PI3K inhibitors, NVP-BKM120 and NVP-BEZ235.341  And 
similar results have been also reported in other publications.342-345  These findings support 
our result that inhibition PI3K, not KRAS, leads to tumor cell growth arrest in MTS.  
Our data suggested that mTOR inhibitors together with PI3K inhibitor might achieve better 
outcome and PI3K inhibitors can be used between chemotherapies and prevent tumor 
regrowth in clinic. Rapamycin was the first available mTOR inhibitor. Presently, FDA has 
also approved temsirolimus and tverolimus, which also target mTOR. Metformin, first used 
in diabetes, also has been reported a PI3K inhibitor and has anticancer activity.346 The oral 
pan-PI3K inhibitor buparlisib (BKM120), that has been tested in clinical phase I, has shown 
positive result in advanced solid tumors.342,343,347,348 All these results predict that treatment of 
rapamycin/temsirolimus/tverolimus combines/sequential with metformin/ buparlisib might be 
worth testing in MTS for the further clinic application. 
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2.2 PAPER II:  
Induction of mitochondrial dysfunction is a strategy for targeting quiescent tumor cells in 
metabolically compromised microenvironments 
Background: Abnormal vascularization of solid tumors leads to the generation of tissue 
microenvironments that are chronically starved of oxygen and nutrients.349,350 Tumor cells 
living in such environment are slowly growing or quiescent and display altered phenotypic 
characteristics when compared with cells located in more vascularized regions.351-353 Such 
non-dividing cells are often resistant to mainstay standard chemotherapies that rely on DNA 
replication and cell division to elicit their antitumor effect.354,355 The altered phenotype of 
quiescent cells enables them to survive chemotherapeutic regimes and reseed nascent tumors 
following secession of chemotherapy.328 
Results: In this paper, we used MTS of HCT116 colon cancer cells to screen a diverse 
chemical library with the aim to find compounds with cytotoxic activity in core, hypoxic, 
regions. And a small molecule compound, VLX600, was identified from this screening and 
shown to decrease mitochondrial oxidative phosphorylation (OXPHOS). 
1. Multicellular spheroids model  
Firstly, we have shown again that multicellular spheroids model can mimic real tumor 
microenvironment and be used in drug screening. Comparison of gene set enrichment 
analysis (GSEA) of microarray data between HCT116 cells grown as monolayers and MCS 
showed upregulation of genes associated with hypoxia and glycolysis (Supplementary Fig. 
1a). Hypoxia was confirmed by staining for pimonidazole adducts (Fig.1a). Cells in MCS 
core regions stained positively for BiP/Grp78 (Fig.1a), an endoplasmic reticulum (ER) 
chaperone. Similar to solid tumor tissue,356-358 and consistent with previous 
reports,84,85,359,360 MCS contain decreased levels of glucose per cell (Supplementary Fig.1c). 
Furthermore, glucose was found to be an essential nutrient for MCS viability since 
decreasing glucose concentrations in the culture medium resulted in death of cells in inner 
areas (Supplementary Fig.1d).  
2. VLX600 reduces multicellular spheroid viability 
VLX600 was the most effective compound found in this screen VLX600 exposure (6 µΜ) 
resulted in the appearance of central necrotic areas after 72–96 h and modest induction of 
active caspase-3 in stained sections (Fig.1C). Importantly, exposure of MCS to VLX600 
resulted in a strong decrease in clonogenicity of dispersed cells. In contrast to the cancer cell 
lines, immortalized epithelial hTERT-RPE1 cells became growth arrested in the absence of 
detectable cytotoxicity (Fig.1h; Supplementary Fig.1g). Furthermore, when non-proliferating, 
confluent hTERT-RPE1 cells were exposed to VLX600, no loss of cell viability was 
observed (Fig.1i). These results suggest that VLX600 displays selective cytotoxic activity 
against malignant cells. 
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3. VLX600 induces glycolytic and autophagic responses 
Thirdly, data indicates that VLX600 induces glycolytic and autophagic responses. HCT116 
MCS were exposed to VLX600 or vehicle for 6h followed by microarray-based gene 
expression analysis. GSEA of genes induced by VLX600 showed a strong positive 
correlation to genes associated with hypoxia, glycolysis. Consistent with the induction of a 
hypoxic gene signature, expression of the hypoxia-inducible factor (HIF-1α) transcription 
factor was upregulated by VLX600 in monolayer cells (Fig.2b). Increase of cellular lactate 
production indicated the induction of glycolysis, which was proved dependent on HIF-1a 
(Fig.2a; Supplementary Fig.2b). HIF-1α knocked out cells grew much slower and appeared 
more sensitive to VLX600 both on monolayer and spheroids.  
VLX600-exposed HCT116 cells increased in size and also showed the presence of large 
cytoplasmic vesicles, which were proved to be autolysosomes. And this phenomenon was 
due to VLX600 inhibition of mTOR downstream effectors 4EBP1 and p70-S6K under a HIF-
1α independent way. The cytotoxic effect of VLX600 was indeed found to be potentiated by 
different autophagy inhibitors. We conclude that VLX600 induced HIF-1α-dependent 
glycolytic and autophagic responses play protective roles on tumor cell survival.  
4. VLX600 induces mitochondrial dysfunction and leads to larger glucose dependence. 
Fourthly, our results have indicated that mitochondrial dysfunction leads to larger glucose 
dependence. We added FCCP to HCT116 cells at different times of VLX600 exposure and 
measured OCR. Already after 90min, uncoupled respiration was impaired (Fig.6a), and no 
stimulation by the uncoupler was observed after 4 h (Fig.6b). Importantly, no effects on p70 
phosphorylation were observed at 90 min, showing that the effect on mitochondria appeared 
earlier than mTOR inhibition. Using digitonin-permeabilized HCT116 cells, we found partial 
inhibition of complex I, II and IV (Fig.6e,f ). If tumor cells grew in a glucose-starved 
condition, their sensitivity to VLX600 would increase, especially HCT116 HIF-1α knock out 
cells (Fig.5g,h). We conclude from these results that VLX600 has profound effects on 
mitochondrial OXPHOS by inhibiting the function of complexes in the electron transport 
chain and made tumor cells more glucose dependent. 
5. VLX600 has shown an antitumor activity in human tumor xenografts 
Finally, VLX600 has shown an antitumor activity in human tumor xenografts. Using the 
maximally tolerated dose (16mg/kg), antitumor activity was observed in both HCT116 and 
HT29 colon cancer xenografts (Fig.7b–e). Importantly, minimal systemic toxicity was 
observed as evidenced by no loss of body mass and no or minor changes in plasma 
parameters such as liver alanine aminotransferase, blood glucose and total protein 
(Supplementary Fig.7a,b). Moreover, synergetic affect was observed with both irinotecan and 
oxaliplatin in vivo (Supplementary Fig.7c). 
Discussion: VLX600, an inhibitor of mitochondrial OXPHOS system, decreases the viability 
of quiescent cells in 3-D tumor spheroids. This might suggest that tumor cells in nutritionally 
compromised microenvironments are sensitive to disturbances of mitochondrial function. 
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Coincidentally, another paper published after us has also shown that drugs toxic to MTS are 
all targeting mitochondria.361 In paper V of my thesis, we have introduced several FDA 
approved reagents that have significant cytotoxic effects on MTS and are mitochondrial 
uncouplers. All these support the hypotheses that, in MTS, tumor cells, especially the inner 
core of the spheroids, are more dependent on functional mitochondria and extracellular 
nutrient concentrations (Figure10) 
Figure 10: Model for the cytotoxic effects of VLX600 on tumor cells. VLX600 impairs OXPHOS and 
induces a HIF-1α-dependent shift to glycolysis. This shift protects tumor cells and normal cells in 
microenvironments where glucose is available. Tumor cells cannot meet their energy demands solely by 
glycolysis, leading to induction of autophagy. In metabolically compromised microenvironments, the ability 
to shift to glycolysis  is limited because of glucose unavailability and lack of HIF-1α-stabilization.  
 
And our results might also suggest more that can be considered in further studies.  
Because of the low supply of oxygen and nutrients in the core of MTS, OXPHOS already 
slows down, if mitochondrial dysfunction only impairs OXPHOS activity and reduces ATP 
production, core cells might not show such a significant sensitivity to VLX600. VLX600 
might also interrupt cell signalling, cell death, as well as maintaining the control of cell 
growth that are also dependent on functional mitochondria. Since it has been shown that the 
gene expression pattern of cells cultured in 3D is much different from that in 2D,310,361,362 
drugs can be preferentially effective in 3D but not in 2D (like nitazoxanide). As the spheroids 
have gradient structures, the out rim of viable cells will average some significant differences. 
It will be really cool, if we can trypsin or cutting out the periphery of spheroids and do gene 
expression analysis or proteomics for the core. We might be able to find some potential 
targets. Of course, we could also use MHOK to mimic the trypsin effect (cells in the out rim 
of the spheroids are dead and off spheroids), which has been shown in paper I, but this might 
also induce changes in gene expression. 
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Spheroids formed in vitro by culturing tumor cells from patients contain cancer stem cells 
(CSC) in the cores. These cells show characters of quiescence and ability of re-proliferation 
under certain conditions.363-367 For the development of novel types of anticancer therapy, only 
those applications that can more efficiently eliminate cancer stem cells will improve 
outcomes. Due to this reason, it is worth testing VLX600 and other drugs, which are more 
toxic to quiescent tumor cells, on cancer stem cell models.  
The mechanism of action of VLX600 is under investigation. Analysis of gene expression 
profiles has suggested that the drug is a metal chelator (Mårten Fryknäs, personal 
communications). The exact spectrum of metals that are chelated is under investigation, but 
iron belongs to this group. The effect on mitochondrial OXPHOS may be due to depletion of 
heme, resulting in inhibition of electron transport. The decrease in COX-1 expression would 
be secondary to heme depletion in the scheme.  
Clinical trials have been initiated with VLX600 and it is worth exploring drugs that will be 
more effective to combine with VLX600. We have mentioned that after VLX600 treatment, 
autophagy and glycolysis up-regulation are rescued responses, so drugs that can inhibit these 
two responses might give better results. Lonidamine (Phase III) and TLN-232 (Phase II) are 
glycolysis inhibitors and already used in clinic trails.368 Lys05, Autophagy inhibitor, has 
shown a good effect alone both in vitro and in vivo.156 Proteasome is another organelle in 
cells that are also responsible for protein degradation and recycling in cells, its inhibitor can 
also be combined with VLX600, For example, velcade and b-AP15.369,370 
Last, but not least, one of the advantages to use 3D models for novel drug development is that 
it takes the penetration ability of the drug candidates into account. Based on the Lipinski’s 
lead-like rules of three, which is a revolution of the rules of five (RO5) and generally 
followed in small molecule library screens,371-374 a lead-like chemical should have 
MW < 300, log P < 3, H-bond donors and acceptors <3 and rotatable bonds <3.374 The logP 
of VLX600 is ≈2.85, this physical character could also contribute to its cytotoxicity to tumor 
spheroids and hard to be considered by using monolayer based screening. The clinically used 
agent cisplatin has a logP of 0.041. Its 6-day IC50 on HCT116 monolayer cells is 0.63µM, 301 
but based on data from Paper I and the previous, even 40µm used on HCT116 spheroids, 
caspase-3 was limited induced around the out-rim of spheroids and did not result in 
eradication of spheroids after 6-days treatment.301,319 These results both strongly suggest the 
necessity of using spheroids for pre-clinical drug discovery. MTS based screens can be 
time-consuming and expensive at beginning but it does give higher chance of success in 
vivo and in clinic. 
In summary, since conventional cytotoxic anticancer agents are significantly less effective 
under conditions of nutrient depletion, so it is necessary to use MTS model for preclinical 
drug screening and testing, at the same time, targeting mitochondrial and induce energy 
catastrophe could be an interesting strategy for therapy.375 
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2.3 PAPER III:  
Autophagy is a protective mechanism for human melanoma cells under acidic stress and 
feasible to be a target in the anticancer therapy. 
Background: Cancer cells are characterized by aerobic glycolysis. An inevitable result of up-
regulated glucose metabolism is tumor acidosis.  
Results: All melanoma cell lines tested were able to slowly proliferate at pH 6.5. All cell 
lines cultured at pH 6.5 continued to slowly proliferate during 72 hours culturing. Even in 
acute exposure to the pH 6.5 medium, some melanoma cells died but surviving cells still 
were able to continue to proliferate. Analysis of LC3 and p62, two indicators for autophagy, 
indicated the activation of autophagy in acidic conditions. We hypothesized that autophagy 
may be a protective mechanism for cancer cells. 
Autophagy upregulation is generally induced as a response to impairment of energy 
supplies,131,142,376-378 it therefore seemed reasonable to hypothesize exposure to acidic 
conditions results in a problem of energy metabolism. Therefore, we measured glucose and 
amino acid uptake in human melanoma cells after exposure to acidic medium. Glucose 
uptake was measured using the fluorescent non-metabolizable glucose analogue 2-NBDG. 
Melanoma cells cultured at acidic pH (pH 6.5) showed a time-dependent reduction in the 
uptake of glucose compared with cells cultured at neutral pH. In line with this observation, 
both ATP and extracellular lactate concentrations were significantly reduced in cells cultured 
at acidic pH, likely as a result of decreased glucose consumption and inhibition of glycolysis. 
Functional autophagy represents a survival strategy for cells under metabolic stress.379-385 To 
determine the role of autophagy in acidic stress-induced cell death we used siRNA to 
knockdown the expression of ATG5, a crucial protein involved in the build-up of 
autophagosomes. Under pH 6.5, cell death was  ~19% in cells treated with scrambled siRNA 
and ~51% in cells treated with ATG5 siRNA (p<0.05). The difference in survival was even 
more pronounced at pH 6.2, where cell death was ~36% in control cells and ~80% under 
conditions of autophagy inhibition. 
Discussion: Autophagy plays a protective role or a suppressed role126,386,387 might much 
depend on tumor stages, so the role of autophagy requires to be checked before using 
autophagy inhibitors or inducers as a combination in experiments or treatments. Based on our 
study, at least in human melanoma, autophagy is a protective mechanism in tumor cells. This 
study might provide support to further therapeutic strategies that inhibits autophagy to kill 
tumor cells, directly or in combination with chemotherapy.  
PH has been gradually believed to be an important factor for keeping tumor cells special 
characters (like drug resistance and metastasis), nowadays treatments based on the pH 
regulation has been proven impactful, for example, Girentuximab (phase III) and Tasigna (in 
clinic use), the inhibitors of carbonic anhydrases 9 that are obviously overexpressed in 
tumor cells, have been used as anti-cancer and anti-metastasis agents.388,389 This indicates 
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that targeting pH regulation in tumor cells represents a novel and attractive therapeutic 
strategy,390-393  as acidic pH is an essential positive regulator of autophagy.124,125 
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2.4 PAPER IV 
Mitochondrial dysfunction induces reduction in c-MYC expression. 
Background: In paper IV, we have continued our studies on VLX600. We are interested in 
the consequences after VLX600 caused mitochondrial dysfunction in tumor cells.  
MYC and Max proteins form heterodimers that bind to promoter E-box sequences to regulate 
gene expression.90,102 MYC overexpression is associated with malignant transformation and 
MYC is necessary for the proliferation of tumor cells. Thus, continuous c-Myc expression is 
required for tumor proliferation in vivo,394 and depletion of MYC leads to proliferative arrest 
of tumor cell lines.395 The MYC protein is a relatively weak transcriptional activator and is 
believed to function as a general enhancer of transcription.396,397 Genes encoding proteins 
involved in cell growth, metabolism, ribosome biogenesis, protein synthesis and 
mitochondrial function are overrepresented as MYC targets.398 The work of several groups 
has established an important role of MYC in supporting mitochondrial biogenesis.110,220,399,400 
MYC affects mitochondrial mass by influencing both mitochondrial fusion and fission, 
favouring the latter process.220  
Results: Firstly, we found inhibition of c-MYC expression by VLX600. During our studies 
we noticed that this compound affected the expression of c-MYC protein in HCT116 colon 
carcinoma cells and in TGR-1 rat fibroblasts. C-MYC expression increased for several hours, 
followed by a decrease. We also examined the effects of VLX600 on the rat cell line HO-
MYC3 where c-MYC is expressed under the control of a retrovirus promoter.401 Interestingly, 
the same pattern of an initial increase followed by a decreased MYC expression was observed 
in these cells. This indicates that MYC expression after VLX600 is not regulated by 
transcription promoters.  
Secondly, the decreased c-MYC mRNA level was observed after exposure to VLX600. We 
examined the effect of VLX600 on c-MYC mRNA levels and found a reduction of c-MYC 
mRNA levels to ~50% after 24 hours of drug exposure. 
Thirdly, destabilization of c-MYC mRNA by VLX600 was found in our experiments. We 
examined the effects of VLX600 on c-MYC mRNA levels in the presence and absence of α-
amanitin, an inhibitor of RNA polymerase II. While VLX600 reduced c-MYC mRNA levels 
~2-fold over 16 hours in the absence of α-amanitin, > 5-fold decreases were observed in the 
presence of VLX600 and the RNA polymerase inhibitor. These observations are consistent 
with VLX600 decreasing c-MYC mRNA stability. 
Fourthly, inhibition of c-MYC expression was observed in other standard mitochondrial 
inhibitors. We compared other standard mitochondrial inhibitors, like oligomycin, rotenone 
and antimycin, and all of them presented similar effects on c-MYC in both HCT116 colon 
carcinoma cells and in TGR-1 rat fibroblasts.  
Finally, the c-MYC-Max interaction inhibitor 10058-F4 was noted to reduce OXPHOS. As it 
was reported that 10058-F4 was a c-MYC-Max inhibitor, then we compared VLX600 with it. 
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As expected, 10058-F4 reduced c-MYC levels over 24 hours. Exposure of HCT116 cells to 
50 µM 10058-F4 resulted in reduction of oxidative consumption rate (OCR). The decrease in 
OCR by 10058-F4 was rapid and unlikely to be mediated by c-MYC. To further address this 
question we examined the effect of 10058-F4 on the c-MYC-/- cell line HO15.19. We found 
that 10058-F4 affected OXPHOS also in these cells, which was showing that the effect is not 
c-MYC-mediated. 
Discussion: Many publications have discussed a lot about mitochondrial function regulated 
by c-MYC, but the mechanism of mitochondria regulating c-MYC has not been stressed 
enough. One original paper, has mentioned that alterations in c-MYC phenotypes resulting 
from dynamin-related protein 1 (Drp1)-mediated mitochondrial fission.402 Here, our data has 
showed that mitochondrial dysfunction leads to down-regulation of c-MYC expression and 
this is a general effect of mitochondrial inhibitors (Rotenone and Antimycin). These results 
might indicate that the mechanism of mitochondria regulating c-MYC is worth exploring.  
How to address the decrease of c-MYC mRNA level after VLX600 will be one issue in our 
following study. It has been reported that if the RNA-binding protein, coding region 
determinant-binding protein (CRD-BP) is attacked, mRNA transcription will be 
interrupted.403 This might be one possible explanation of decrease of c-MYC mRNA level 
after VLX600. Refer to our data of destabilization of mRNA after VLX600, we assume it 
might be regulated by miRNA, since it has been shown that miRNA-494 targets c-MYC404,405 
and locates in mitochondria. If this can be evidenced, mitochondrial dysfunction reduced c-
MYC expression after VLX600 exposure could also be explained.  
Besides reduction of mRNA level, the c-MYC decrease at protein level should also be a 
possibility to explain c-MYC de-regulation after VLX600. It has been reported that mTOR 
inhibition and p70-S6K reduction control c-MYC translation;406 USP37 regulates c-MYC407 
and long none-coding RNA transcript 1 (lncRNA-GHET1) is high expressed in gastric 
carcinoma.408 Possible mechanisms are summarized below in Figure 11. 
 
 
Figure11: Possible mechanisms involved in c-MYC reduction after mitochondrial inhibitors 
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In human, the c-MYC oncogene is overexpressed in at least 40% of cancers and serves as a 
"master regulator" of cellular metabolism and proliferation.89,93,94 But, there is still No drug 
that targets c-MYC has been shown a strong antitumor effect in animal models, and no such 
drug has to my knowledge been tested in clinical trials. Our finding has suggested that 
targeting mitochondria could be an alternative strategy of indirectly regulating c-MYC.  
Some review about c-MYC has mentioned that the ability of cells to grow under hypoxic 
conditions partly because of the crosstalk between hypoxia-inducible factors (HIFs) and the 
c-MYC. And when O2 levels return to normal, c-MYC can help tumor cells return to rapid 
proliferation.409 In Paper II, our results have shown that even withdrawing VLX600 after 3 
days treatment, the effect of VLX600 still exists and spheroids are unable to grow back. This 
possibly indicates that inhibiting c-MYC is another strategy to prevent cells growing back in 
solid tumors. As mentioned above, metformin that has already been used in clinic is a 
mitochondrial complex I inhibitor,269,410 and nitazoxanide (descried in paper V), which is a 
FDA approved anthelmintic drug, has shown an effect of mitochondrial inhibition and c-
MYC reduction in spheroids.411 Both drugs can be continuously taken by patients.412-414 So c-
MYC inhibition by these two drugs might able to be used between cycles of chemotherapy in 
order to inhibit tumor cells growing back. But this assumption needs to be verified firstly by 
spheroids based study in vitro. 
In Summary, the mechanism of mitochondria regulating c-MYC is worth exploring. 
Targeting mitochondria can be a therapeutic strategy in c-MYC overexpressed tumors and 
metformin/ nitazoxanide might be used in sequential chemotherapy to inhibit cancer relapse. 
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2.5 PAPER V 
GFP-labeled HCT116 cells cultured in 384-well plates were used for high-
throughput screening. Nitazoxanide, an FDA-approved antihelminthic drug, was identified 
as a potential candidate for treatment of solid tumors.     
Background: The 3D model was developed to mimic the tumor microenvironment, which is 
hypoxic, nutrient deprived and extracellular acidic. Multicellular tumor spheroids (MCTS) 
were formed in 384-well plates using GFP-labelled HCT116 colon cancer cells. Based on this 
model, 1600 clinically active compounds were screened and followed by hit-validation. 
Results: After comparing the activities in our MTS model with that in 2D-cultures, five 
compounds with 3D-specific activity were identified, nitazoxanide, niclosamide, closantel, 
pyrvinium pamoate and salinomycin. It is noteworthy that, the five most active hits identified 
were all compounds reported to target mitochondria, supporting our previous finding that 
respiration is an attractive target in solid tumors.415 Then we verified the five compounds on 
HCT116 cells and the mitochondrial oxygen consumption rates were measured using 
Seahorse XF analyzer. Nitazoxanide, niclosamide and closantel, which have similar effect as 
FCCP, increased OCR at low concentrations while as the concentration increased, the period 
of elevated OCR became shorter and was followed by shutdown of mitochondrial respiration, 
indicated by a rapid decrease of OCR. The effect of the pyrvinium pamoate and salinomycin 
was different from what was observed for the uncouplers, but both of them also cause 
mitochondrial dysfunction after several hours treatment. 
We further demonstrated that mitochondria are able to recover from exposure to the tested 
OXPHOS inhibitors. It was evident from assessment of OCR in drug-free medium following 
exposure of HCT116 to nitazoxanide for 24 h. OCR gradually increased after removal of the 
drug and returned to normal levels after 7 days. Thus, continuous drug exposure is required to 
eliminate tumor re-growth potential. This is an important finding considering an optimal 
treatment schedule for compounds targeting mitochondria. 
Among the five compounds, nitazoxanide, which is a FDA-approved antiprotozoal drug, has 
an excellent pharmacokinetic and safety profile. This character makes it suitable to be 
continuously treated on patients. So we finally selected it for further evaluation and 
demonstrated strong anti-tumor activity in vivo when combined with a standard 
chemotherapeutic agent.  
In paper V, we tried to explain the reason of the nitazoxanide toxicity to cancer cells that 
agreed with our previous finding (paper II). This made us believe that anticancer drugs, 
which target mitochondria, might have better clinical effects on solid tumors treatment. 
Moreover, different tolerations to energetic deficiency between tumor cells and normal cells 
can be a therapeutic target in cancer treatment. 
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3 CONCLUSION 
The 3-D multicellular spheroid model can be used to discover new drugs that target 
quiescent cancer cells. 
 
• 3-D multicellular spheroids are characterized by its cellular hetergeneity that is able to 
mimic the in vivo tumor microenvironment where large proliferating tumor cells are in 
the periphery and smaller quiescent tumor cells are in the core of the spheroids. 
• 3-D multicellular spheroids can be used to study tumor cell regrowth after cytotoxic 
therapy. This application enables us to find new drug combinations that might have 
higher chance to obtain satisfied effects in clinic.  
• Screening in the 384-well format using GFP-labelled multicellular spheroids is reliable, 
reproducible and time saving, and promises to be useful for future drug screening 
projects.  
 
 
Induction of mitochondrial dysfunction as a strategy for targeting quiescent tumor cells in 
metabolically compromised microenvironments. 
 
• Compounds screened by 3-D multicellular spheroids are likely to be mitochondrial 
inhibitors (paper II and paper V). 
• Mitochondrial dysfunction induces tumor cell energy catastrophe in both proliferating 
and quiescent tumor cells but not normal cells.  
• Mitochondrial dysfunction makes both proliferating and quiescent cells more addicted to 
glucose by up-regulation of glycolysis. Quiescent tumor cells are likely to be more 
sensitive to mitochondrial inhibitors due to low glucose availability.  
• Tumor cells have rescue responses (like autophagy and glycolysis up-regulation) after 
treatment in order to survive.  
• Mitochondrial dysfunction can decrease c-MYC levels: targeting mitochondria can be an 
indirect method to inhibit c-MYC in tumor cells. 
 
VLX600 combination therapy is worth testing on 3-D multicellular spheroids model. 
• VLX600 will be combined with other compounds that are already used in clinic trial. 
Combining VLX600 with compounds that target proliferating cells may be expected to 
result in improved tumor control. 
• VLX600 would be interesting to combine with compounds that inhibit autophagy or 
disturb glucose uptake.  
• VLX600 is currently being evaluated in combination with radiotherapy on solid tumors, 
due to its ability of reducing hypoxia in spheroids.  
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